Table 3.
MS risk assessment (Crude OR) of medical histories
| Variables/medical history | Reference group (Crude OR (95%CI)) | ||
|---|---|---|---|
| Patient control | Normal population | All controls | |
| Depression | (0.77, 0.48–1.23) | (3.1, 1.69–5.96) | (1.32, 0.86–2.05) |
| Measles | (1.18, 0.66–2.10) | (4.67, 1.99–10.94) | (1.95, 1.14–3.32) |
| Rubella | (1.09, 0.47–2.54) | – | (2.25, 0.97–5.21) |
| Mumps | (1, 0.98–1.02) | (5.34, 1.99–14.3) | (1.30, 0.75–2.24) |
| Chickenpox | (0.98, 0.92–1.04) | (4.35, 2.67–7.10) | (0.99, 0.96–1.01) |
| Influenza | (1.34, 0.29–6.06) | (1.34, 0.29–6.06) | (1.34, 0.37–4.80) |
| Migraine | (0.44, 0.27–0.70) | (13.9, 4.20–46.1) | (1.03, 0.66–1.62) |
| Seizure | (0.08, 0.01–0.37) | – | (0.18, 0.04–0.78) |
| Parkinson | (0.74, 0.25–2.17) | (6.15, 0.73–51.5) | (1.3, 0.47–3.82) |
| Headache | (0.21, 0.10–0.45) | (9.37, 1.17–74.7) | (0.46, 0.21–0.97) |
| Epilepsy | (0.10, 0.01–0.84) | – | (0.21, 0.02–1.7) |
| Amnesia | (0.68, 0.25–1.84) | – | (1.41, 0.53–3.77) |
| Hypothyroidism | (0.49, 0.23–1.05) | (1.1, 0.45–2.66) | (0.69, 0.34–1.40) |
| Hyperthyroidism | (1.06, 0.87–1.30) | – | (1.1, 0.85–1.42) |
| Type 1 diabetes mellitus | (1, 0.06–16) | (0.49, 0.04–5.53) | (0.66, 0.06–6.43) |
| Psoriasis | – | (2.01, 0.18–22.3) | (4.03, 0.36–44.7) |
| Myasthenia gravis | (3.82, 1.04–13.9) | – | (7.70, 2.12–27.9) |
| Hypertension | (0.17, 0.03–0.79) | (2.01, 0.18–22.3) | (0.32, 0.07–1.47) |
| Type 2 diabetes mellitus | (0.20, 0.05–0.71) | (1, 0.19–5.01) | (0.34, 0.09–1.18) |
| Kidney disease | (0.82, 0.24–2.76) | (0.82, 0.24–2.76) | (0.82, 0.28–2.38) |
| Family history of type 1 diabetes mellitus | – | (0.26, 0.07–0.95) | (0.53, 0.14–1.95) |
| Family history of Leukemia | (0.19, 0.02–1.69) | (0.19, 0.02–1.69) | (0.19, 0.02–1.54) |
| Family history of MS | (1.42, 0.67–2.98) | (9.79, 2.24–42.7) | (2.53, 1.25–5.15) |
| Head trauma | (1.99, 1.12–3.54) | (4.03, 1.99–8.14) | (2.69, 1.62–4.47) |
| Antibiotic consumption for 2 wk or more during the last 3 yr | (1.33, 0.78–2.27) | (1.39, 0.81–2.38) | (1.36, 0.86–2.15) |
| Antibiotic consumption between 13–19 years old | (2.48, 0.86–7.20) | (3.12, 0.99–9.86) | (2.77, 1.14–6.69) |
| Co-Amoxiclav (using ≥ 2 wk during the last 3 yr) | (1.62, 0.52–5.05) | (0.88, 0.33–2.34) | (1.14, 0.47–2.78) |
| Cefixime (using ≥ 2 weeks during the last 3 yr) | (1.17, 0.38–3.55) | (3.5, 0.73–17.5) | (1.77, 0.63–4.97) |
| Cefalexin (using ≥ 2 weeks during the last 3 years) | (2.38, 0.60–9.34) | (7.21, 0.87–59.2) | (3.5, 1.03–12.4) |
| Azithromycin (using ≥ 2 wk during the last 3 yr) | (1.77, 0.51–6.16) | (1.77, 0.51–6.16) | (1.77, 0.63–4.97) |
| Amoxicillin (using ≥ 2 wk during the last 3 yr) | (2.72, 1.11–6.68) | (4.84, 1.60–14.5) | (3.49, 1.61–7.55) |
| Metronidazole (using ≥ 2 wk during the last 3 yr) | (1.25, 0.33–4.74) | – | (2.5, 0.67–9.55) |
CI = confidence interval, MS = multiple sclerosis, OR = odds ratio.